This is indeed the case in the EMT6-CDDP primary tumor model when treated with all CTX regimens, especially in CTX140 1q6d where CD4+ effector memory T cells (CD4+ CD44+ CD62L−) were reduced to a third of control treated and CD8+ effector memory T cells were reduced by roughly two thirds of control treatment (Supplementary Fig. 3). The gene discussed is CD4; the disease is neoplasm.